EHRA Premium Access

Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Event: EHRA 2019
Topic: Stroke Treatment, Other
Session type: Satellite Symposium
Sponsored by Daiichi Sankyo, Europe
Date: 19 March 2019
Time: 12:45 - 13:45

Congress Session

5 presentations in this session

Welcome and Introduction - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Speaker: Professor S. Hohnloser (Frankfurt, DE)
Thumbnail

ELIMINATE-AF trial in the context of other non-vitamin K antagonist oral anticoagulant trials.

Speaker: Professor J. Kautzner (Prague, CZ)
Thumbnail

Implications of non-vitamin K antagonist oral anticoagulant trials in ablation practice.

Speaker: Doctor M. Grimaldi (Acquaviva Delle Fonti, IT)
Thumbnail

Current recommendation for atrial fibrillation patients undergoing ablation.

Speaker: Professor J. Steffel (Zurich, CH)
Thumbnail

Panel discussion and closing remarks - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?

Speaker: Professor S. Hohnloser (Frankfurt, DE)
Thumbnail

5 speakers from this session

Professor Stefan H Hohnloser

Johann Wolfgang Goethe University, Frankfurt (Germany)
27 presentations
1 follower

Professor Josef Kautzner

Institute for Clinical and Experimental Medicine (IKEM), Prague (Czechia)
27 presentations
3 followers

Doctor Massimo Grimaldi

Regional General Hospital F. Miulli, Acquaviva Delle Fonti (Italy)
2 presentations
0 follower

Professor Jan Steffel

Swiss EP AG, Zurich (Switzerland)
57 presentations
9 followers

Professor Stefan H Hohnloser

Johann Wolfgang Goethe University, Frankfurt (Germany)
27 presentations
1 follower

This platform is supported by

logo Novo Nordisk